Health care stocks were mixed premarket Monday with the iShares Biotechnology ETF (IBB) 0.2% higher and the Health Care Select Sector SPDR Fund (XLV) down 0.2% recently.
Twist Bioscience (TWST) shares advanced by over 13% after the company reported a narrowed fiscal Q4 loss as revenue increased during the period.
Shares of Regenxbio (RGNX) rose by over 22% after the company reported new, positive data from the phase I/II portion of a study evaluating RGX-202 gene therapy for Duchenne muscular dystrophy.
Cybin (CYBN) shares were almost 13% higher after the company said data from a phase 2 study show that CYB003, a potential adjunctive treatment for major depressive disorder, offers "sustained relief" through one year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。